Welldoc Achieves 50+ Patents, Unveiling "CGM-GPT" for Advanced Glucose Prediction
Digital Health Leader's Innovation in Real-Time Sensor-Based AI Sets New Standards for Personalized Cardiometabolic Care
COLUMBIA, Md., March 19, 2025--(BUSINESS WIRE)--Welldoc®, a digital health leader revolutionizing cardiometabolic care, today announced the issuance of four new patents, marking its 54th patent grant. This milestone underscores Welldoc's relentless commitment to innovation and leadership in leveraging artificial intelligence (AI) and advanced predictive capabilities based on real-time sensor data. The company's digital health platform empowers individuals with personalized AI-driven digital coaching to enable self-management of cardiometabolic conditions, positive lifestyle changes and improved overall health and outcomes.
The new patents focus on Welldoc's unique approach to combining dense, sensor-based data specifically collected from Continuous Glucose Monitors (CGM), with AI to predict future engagement levels, health metrics and improved outcomes. This includes the development of a "CGM-GPT" model using generative AI techniques to predict future glucose values.
"Securing 50+ patents is a testament to the hard work of our talented team in the U.S. and India and their dedication to driving AI innovation in digital health," said Kevin McRaith, President and CEO of Welldoc. "We are proud to have built a strong foundation of intellectual property that enables us to deliver impactful cardiometabolic care solutions and drive continuous innovation in our product development. Protecting the underlying algorithms and functions that power the Welldoc platform is crucial to our ability to partner with healthcare industry leaders and create a more sophisticated, personalized experience for our users."
Welldoc continues to expand its intellectual property portfolio, securing protections for a wide range of AI-driven and CGM-focused innovations. These include machine learning algorithms based on aggregated, complex health data—such as medications, symptoms and device data—and generative AI algorithms for curated content delivery along with first-in-class advanced capabilities in quantitative prediction, including weight and glucose levels.
"It is well-known that generative, transformer-based AI models—most commonly known as large language models—may not work well for complex mathematical applications. They were designed to predict a series of words rather than numerical values," said Anand Iyer, PhD, MBA, Chief AI Officer of Welldoc. "We are creating our own specialized large sensor models, designed to tackle complex mathematical tasks, such as predicting future glucose levels, ultimately focused on advanced improvement to personalized health."
Welldoc currently has patents granted and pending in the U.S. and globally, with plans to expand.
About WelldocWelldoc®, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc's comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. Welldoc is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs.
Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform, and an IP portfolio of 50+ patents for its advanced AI and first-in-class tech. With over 90 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Welldoc is an industry thought leader and has been showcased in prestigious conferences and publications, including South by Southwest, The Wall Street Journal and The Economist. The company has been named the "Best Overall Digital Health Company" by MedTech Breakthrough for the past two years and was selected as a winner of the 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. For more information, visit www.welldoc.com. Follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319208869/en/
Contacts
CTD CommsMegan Prock McGrath573-578-1184megan@ctdcomms.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 hours ago
- Business Wire
ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abacus Global Management, Inc. ('Abacus' or 'the Company') (NASDAQ: ABL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abacus is the subject of a report issued by Morpheus Research on June 4, 2025, titled: 'Abacus Global Management: This $794 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue by Systematically Underestimating When People Will Die.' According to the report, the Company changed its portfolio valuation methodology to make it appear more profitable than it actually is. The report also alleges that the Company uses unusual methodologies to calculate life expectancy estimates and its co-founders have 'red flags' in their past. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Upturn
a day ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
2 days ago
- Yahoo
Earn up to 110,000 bonus miles with a new Delta SkyMiles credit card
American Express and Delta are out with all-new welcome bonus offers across three personal credit cards within the Delta SkyMiles suite: Delta SkyMiles® Gold American Express Card: Earn 80,000 bonus miles after spending $3,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Platinum American Express Card: Earn 90,000 bonus miles after spending $4,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Reserve American Express Card: Earn 100,000 bonus miles after spending $6,000 on eligible purchases in your first six months of card membership. There are also new offers on Delta business cards: Delta SkyMiles® Gold Business American Express Card: Earn 90,000 bonus miles after spending $6,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Platinum Business American Express Card: Earn 100,000 bonus miles after spending $8,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Reserve Business American Express Card: Earn 110,000 bonus miles after spending $12,000 on eligible purchases in your first six months of card membership. With over 290 destinations across six continents and more than 200 million customers served in 2024, Delta is one of the most well-known airlines worldwide. And you could reduce much of the upfront cost of flying to one of Delta's global destinations if you're able to take advantage of these generous sign-up bonuses. It depends on how you redeem the miles, but we value Delta SkyMiles at an average of 1.18 cents each. That means 100,000 miles equals about $1,180. However, as with many airline credit cards, the exact value of your miles depends on how you use them. Since Delta uses dynamic pricing, you can see different values with each redemption. You can find plenty of value with 100,000 (give or take, depending on the welcome offer) Delta SkyMiles. This is especially true when accounting for the TakeOff 15 benefit, which provides an automatic 15% discount on eligible award flights for Delta SkyMiles cardholders. Let's take a look at some possible redemptions. You can fly from Los Angeles (LAX) to Auckland (AKL) for 38,200 miles. The cash price for the same flight is $1,341, giving you a redemption value of about 3.5 cents per mile ($1,341 / 38,200 = 0.035104). You'll still have plenty of miles left to figure out your return flight, which could mean including a stop in Australia after visiting Hobbiton (and while you're in the area). This flight from Salt Lake City (SLC) to Mexico City (MEX) will only set you back 26,300 miles. The redemption value for this flight is about 1.5 cents per mile, which is better than our average valuation. And with miles to spare, you can bring some friends or work on covering the return leg home. You don't have to get fancy with your redemptions; a short flight will do just fine if it saves you money, especially if it's a route you frequently take. Consider this example: A flight between Atlanta (ATL) and Miami (MIA) that costs 8,300 miles or $117. With 100,000 miles, you could take this flight 12 times, giving you plenty of opportunities for vacations or visiting friends and family. This particular flight has a redemption value of about 1.4 cents per mile. See which flavor — Gold, Platinum, or Reserve — of Delta SkyMiles card is the best fit for you. Consider which Delta SkyMiles business card is right for you if you run a small best Delta SkyMiles credit card for you depends on your goals and spending habits. If you only fly occasionally, maybe a few times per year, we recommend the Delta SkyMiles Gold Amex Card. This card has the lowest annual fee but still provides one of the best benefits: a free checked bag. With only a few roundtrip flights, you can offset the annual fee in saved baggage charges. If you travel a lot, a card like the Delta SkyMiles Platinum Amex Card or Delta SkyMiles Reserve Amex Card may make more sense. These cards have higher annual fees, but they also provide more benefits. For example, the Delta Reserve Amex Card offers Delta Sky Club Access (at least 15 visits each Medallion year), which could come in handy the more you find yourself in airports. Business owners can apply for the personal or business versions of the Delta SkyMiles credit cards. The business credit cards are largely the same as their personal variants, but their welcome offers require increased spending, so keep that in mind when making your decision. All the Delta SkyMiles credit cards associated with these new welcome offers have annual fees. If you want to avoid an annual fee at all costs, consider no-annual-fee credit Disclosure: The information in this article has not been reviewed or approved by any advertiser. All opinions belong solely to the Yahoo Finance and are not those of any other entity. The details on financial products, including card rates and fees, are accurate as of the publish date. All products or services are presented without warranty. Check the bank's website for the most current information. This site doesn't include all currently available offers. Credit score alone does not guarantee or imply approval for any financial product.
